- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957382
Evaluation of Safety and Efficacy of the Accero® (Heal) Stent for Intracranial Aneurysm Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Acandis GmbH
- Phone Number: +49 7231 155 00 0
- Email: info@acandis.com
Study Locations
-
-
-
Berlin, Germany, 12351
- Recruiting
- Vivantes - Klinikum Neukölln Institut für klinische und interventionelle Neuroradiologie
-
Contact:
- Dr. Alexander Bock
-
Hamburg, Germany, 20246
- Recruiting
- Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Dr. Maxim Bester
-
Meppen, Germany, 49716
- Recruiting
- Krankenhaus Ludmillenstift, Abteilung für Radiologie, Neuroradiologie und Nuklearmedizin
-
Contact:
- Ekin Celik, Dr.
-
Recklinghausen, Germany, 45657
- Recruiting
- KLINIKUM VEST GMBH Knappschaftskrankenhaus Klinik für Radiologie und Neuroradiologie
-
Contact:
- Christian Loehr, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All patients treated with Accero® (heal) Stent according to IFU
Exclusion Criteria:
- mRS > 2
- Hunt and Hess >3 (in patients with subarachnoid hemorrhage-SAH)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Raymond Roy Classification
Time Frame: 6 months after treatment
|
Assessment of Raymond Roy Classification
|
6 months after treatment
|
Raymond Roy Classification
Time Frame: 12 months after treatment
|
Assessment of Raymond Roy Classification
|
12 months after treatment
|
Raymond Roy Classification
Time Frame: 24 months after treatment
|
Assessment of Raymond Roy Classification
|
24 months after treatment
|
Raymond Roy Classification
Time Frame: 36 months after treatment
|
Assessment of Raymond Roy Classification
|
36 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified Rankin Scale (mRS)
Time Frame: 6 months after treatment
|
Assessment of modified Rankin Scale Modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities. The scale runs from 0-6: 0 - No symptoms.
|
6 months after treatment
|
modified Rankin Scale (mRS)
Time Frame: 12 months after treatment
|
Assessment of modified Rankin Scale Modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities. The scale runs from 0-6: 0 - No symptoms.
|
12 months after treatment
|
modified Rankin Scale (mRS)
Time Frame: 24 months after treatment
|
Assessment of modified Rankin Scale Modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities. The scale runs from 0-6: 0 - No symptoms.
|
24 months after treatment
|
modified Rankin Scale (mRS)
Time Frame: 36 months after treatment
|
Assessment of modified Rankin Scale Modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities. The scale runs from 0-6: 0 - No symptoms.
|
36 months after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maxim Bester, PD. Dr., Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Universitätsklinikum Hamburg-Eppendorf
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1041-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Aneurysm
-
University of FloridaCompletedIntracranial Aneurysm | Aneurysm, Intracranial | Giant Intracranial AneurysmUnited States
-
Centre hospitalier de l'Université de Montréal...RecruitingIntracranial Hemorrhage Ruptured AneurysmUnited States, Canada, Spain
-
Universitätsklinikum Hamburg-EppendorfRecruitingAneurysm | Aneurysm, Intracranial | Aneurysm Cerebral | Aneurysm, Brain | Aneurysm of Cerebral ArteryGermany
-
Merlin MD Pte LtdRecruitingIntracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm, LesionSpain
-
Stryker NeurovascularStryker (Beijing) Healthcare Products Co., LtdTerminated
-
Beijing Tiantan HospitalGuangzhou Red Cross Hospital; The First Dongguan Affiliated Hospital of Guangdong... and other collaboratorsRecruiting
-
Hospices Civils de LyonNot yet recruitingIntracranial Sacciform Aneurysm
-
Cerus Endovascular, LtdRecruitingAneurysm, IntracranialUnited States
-
Fondation Ophtalmologique Adolphe de RothschildActive, not recruitingIntracranial Aneurysms | Ruptured AneurysmFrance
-
Stryker NeurovascularActive, not recruitingAneurysm, IntracranialUnited States, Canada, Australia
Clinical Trials on Accero® (heal) Stent
-
Acandis GmbHRecruiting
-
Hyeon-Cheol GwonTerumo Corporation; Meril Life Sciences Pvt. Ltd.UnknownIschemic Heart DiseaseKorea, Republic of
-
Swiss Vision NetworkActive, not recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Primary Open Angle
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted
-
Chinese University of Hong KongTerminated
-
Cordis CorporationCompletedSuperficial Femoral Artery DiseaseUnited States
-
Cook Research IncorporatedCompletedAortic Aneurysm, AbdominalUnited States
-
W.L.Gore & AssociatesCompleted
-
Cook Research IncorporatedCompleted